Genotyping and Phenotyping of CYP2D6 Breast Cancer Patients on Tamoxifen

Biological Response to Tamoxifen (TAM) in Patients With Breast Cancer Non Metastatic RH+

NCT01220076 ·Status: COMPLETED ·Phase: PHASE2

Tamoxifen Pharmacogenetics in Asian Breast Cancer Women

NCT01181518 ·Status: UNKNOWN

Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen

NCT00764322 ·Status: COMPLETED ·Phase: PHASE2

Study of Tamoxifen Dose Escalation in Breast Cancer Patients With CYP2D6 Polymorphisms

NCT01075802 ·Status: COMPLETED ·Phase: NA

Dose-determining and Dose-confirmatory Study to Investigate the Optimal Dose of Tamoxifen in Breast Cancer Patients According to Genotype Status of TCF20 rs932376

NCT04961632 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

Study of Cytochrome P450 Polymorphisms (CYP2D6, CYP3A4/5 and CYP2C19) in Breast Cancer Patients

NCT01169792 ·Status: COMPLETED

Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer

NCT03351062 ·Status: RECRUITING ·Phase: PHASE3

The Clinical and Economic Impact of Pharmacogenomic Testing for Tamoxifen Metabolism in Postmenopausal Women Receiving Tamoxifen for Prevention of Recurrent Breast Cancer

NCT00830973 ·Status: COMPLETED

Effect of Pharmacogenomics Differences in Phase I and II Metabolism of Tamoxifen on Efficacy and Toxicity

NCT00886535 ·Status: COMPLETED

Tamoxifen Pharmacokinetics and CYP2D6 Polymorphisms in Asian Women With Hormone Receptor Positive Breast Cancer

NCT00717015 ·Status: COMPLETED

Genotype and Phenotype Guided Supplementation of TAMoxifen Standard Therapy With ENDOXifen in Breast Cancer Patients

NCT03931928 ·Status: COMPLETED ·Phase: PHASE2

Genetic Risk Estimation of Breast Cancer Prior to Preventive Medication Uptake

NCT02517593 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

A Pilot Study of Varying Doses of Tamoxifen in the Setting of Genetic Polymorphisms of CYP2D6

NCT00900744 ·Status: COMPLETED

Pharmacogenetics as a Predictor of Toxicity in Pre-Menopausal Women Receiving Doxorubicin and Cyclophosphamide in Early Breast Cancer

NCT00352872 ·Status: TERMINATED

Prevalence of Genetic Polymorphisms in Genes Coding for Tamoxifen Metabolising Enzymes

NCT00966043 ·Status: COMPLETED

Tamoxifen Pharmacogenetics and Clinical Effects

NCT00228930 ·Status: COMPLETED

Tamoxifen in Preventing Breast Cancer in Women at Increased Risk for Breast Cancer

NCT00096369 ·Status: TERMINATED ·Phase: PHASE2

Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer

NCT01293032 ·Status: COMPLETED ·Phase: NA

Safety of Toremifene and Tamoxifen Therapy in Premenopausal Patients With Operable Breast Cancer

NCT02344940 ·Status: COMPLETED ·Phase: PHASE4

Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer

NCT02311933 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Analyzing a New Mechanism in Response to Tamoxifen Therapy in Breast Cancer Patients

NCT01027416 ·Status: COMPLETED ·Phase: NA

Examination of Breast Cancer Cells of Pre-menopausal and Post-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant.

NCT02936206 ·Status: TERMINATED ·Phase: PHASE1

Neoadjuvant Hormonal Therapy Compared to Neoadjuvant Chemotherapy in Stage IIIB/C and IV Breast Cancer Patients

NCT02995772 ·Status: COMPLETED ·Phase: PHASE3

Arzoxifene or Tamoxifen in Preventing Breast Cancer in Premenopausal Women at High Risk for Breast Cancer

NCT00253539 ·Status: COMPLETED ·Phase: PHASE2

Tamoxifen Study

NCT00000529 ·Status: COMPLETED ·Phase: PHASE3